price
NT
NASDAQ · NTLA
Intellia Therapeutics, Inc.
Healthcare · Biotechnology
$12.21
Down-$0.28 (-2.29%)
Updated Sep 10, 2026, 11:13 PM
SID Score
4.1/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1B
- P/E ratio
- -2.36
- Dividend yield
- 0.00%
- 52-week range
- $10.15 – $18.48
- Volume
- 4.93M
- Avg. volume
- 8.04M
Price performance
NTLA price history
1M range · 20 trading sessions · Daily adjusted prices
NTLA closed at $12.21 after 20 trading sessions, up 0.99% for the selected period.
- Last close
- $12.21
- Period change
- +0.99%
- Period low
- $11.60
- Period high
- $13.51
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 9, 2026 | $12.50 | $12.82 | $12.19 | $12.21 | 4.93M |
| Sep 8, 2026 | $12.83 | $12.89 | $12.425 | $12.74 | 4.13M |
| Sep 4, 2026 | $12.59 | $12.96 | $12.52 | $12.74 | 2.8M |
| Sep 3, 2026 | $12.86 | $12.92 | $12.40 | $12.68 | 3M |
| Sep 2, 2026 | $12.67 | $13.13 | $12.28 | $12.76 | 3.25M |
| Sep 1, 2026 | $12.52 | $12.81 | $12.34 | $12.685 | 2.18M |
| Aug 31, 2026 | $12.64 | $12.85 | $12.44 | $12.73 | 2.93M |
| Aug 28, 2026 | $13.11 | $13.49 | $12.68 | $12.87 | 3.44M |
| Aug 27, 2026 | $13.26 | $13.45 | $13.00 | $13.11 | 2.45M |
| Aug 26, 2026 | $13.38 | $13.50 | $12.98 | $13.19 | 2.71M |
| Aug 25, 2026 | $12.84 | $13.73 | $12.76 | $13.51 | 4.09M |
| Aug 24, 2026 | $12.60 | $12.79 | $12.24 | $12.56 | 3.12M |
| Aug 21, 2026 | $12.65 | $13.13 | $12.65 | $12.84 | 3.35M |
| Aug 20, 2026 | $12.95 | $13.04 | $12.29 | $12.44 | 4.7M |
| Aug 19, 2026 | $12.10 | $13.35 | $12.01 | $13.28 | 6.11M |
| Aug 18, 2026 | $11.80 | $12.10 | $11.44 | $11.60 | 3.18M |
| Aug 17, 2026 | $11.91 | $12.2195 | $11.75 | $12.09 | 1.82M |
| Aug 14, 2026 | $11.83 | $12.0389 | $11.41 | $11.91 | 2.36M |
| Aug 13, 2026 | $12.105 | $12.1733 | $11.81 | $11.83 | 2.95M |
| Aug 12, 2026 | $12.06 | $12.31 | $11.88 | $12.09 | 2.04M |
Latest NTLA news
The latest Smart Investors Daily articles mentioning NTLA.
Stock researchResearch & News · Analysis
Loading stock research…

